Win Advisors Inc. Buys New Stake in CVS Health Co. (NYSE:CVS)

Win Advisors Inc. purchased a new stake in shares of CVS Health Co. (NYSE:CVS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,668 shares of the pharmacy operator’s stock, valued at approximately $211,000.

Several other hedge funds have also modified their holdings of CVS. Atticus Wealth Management LLC lifted its holdings in CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after buying an additional 219 shares during the period. Cornerstone Planning Group LLC increased its position in shares of CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 243 shares in the last quarter. ZRC Wealth Management LLC grew its position in CVS Health by 400.0% in the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after purchasing an additional 400 shares in the last quarter. Coston McIsaac & Partners grew its position in CVS Health by 42.6% in the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock valued at $42,000 after purchasing an additional 161 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners bought a new position in CVS Health in the fourth quarter valued at $50,000. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Down 17.6 %

NYSE CVS traded down $11.95 on Wednesday, hitting $55.76. The company’s stock had a trading volume of 29,832,984 shares, compared to its average volume of 10,842,268. CVS Health Co. has a 1-year low of $54.00 and a 1-year high of $83.25. The company has a quick ratio of 0.63, a current ratio of 0.86 and a debt-to-equity ratio of 0.77. The company’s 50-day moving average is $74.05 and its 200 day moving average is $73.62. The firm has a market cap of $70.28 billion, a PE ratio of 8.58, a PEG ratio of 0.89 and a beta of 0.52.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.11. The company had revenue of $93.81 billion during the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. CVS Health’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.99 earnings per share. As a group, analysts predict that CVS Health Co. will post 8.31 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Monday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.77%. The ex-dividend date is Friday, April 19th. CVS Health’s payout ratio is currently 41.18%.

Insider Activity at CVS Health

In related news, EVP Prem S. Shah sold 29,473 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now owns 39,765 shares in the company, valued at $3,059,916.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.24% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CVS shares. Wells Fargo & Company decreased their target price on shares of CVS Health from $83.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 8th. SVB Leerink started coverage on shares of CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price objective for the company. Piper Sandler lifted their price objective on shares of CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Royal Bank of Canada decreased their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research report on Thursday, February 8th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of CVS Health in a research report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.